Literature DB >> 29296924

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Geling Li1, Emily Waite2, Julie Wolfson3.   

Abstract

A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 JAK3-activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

Entities:  

Year:  2017        PMID： 29296924      PMCID： PMC5745136          DOI： 10.1182/bloodadvances.2017010470

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  24 in total

1.  How I treat prolymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.

Authors:  Anna Stengel; Wolfgang Kern; Melanie Zenger; Karolína Perglerová; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach
Journal:  Genes Chromosomes Cancer       Date:  2015-10-23       Impact factor: 5.006

3.  Management of prolymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

4.  Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Authors:  D Bellanger; V Jacquemin; M Chopin; G Pierron; O A Bernard; J Ghysdael; M-H Stern
Journal:  Leukemia       Date:  2013-09-19       Impact factor: 11.528

5.  Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.

Authors:  Biju Krishnan; Monica Else; Geir E Tjonnfjord; Bruno Cazin; Dennis Carney; John Carter; Nicolas Ketterer; Daniel Catovsky; Mark Ethell; Estella Matutes; Claire E Dearden
Journal:  Br J Haematol       Date:  2010-03-01       Impact factor: 6.998

6.  Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.

Authors:  J T Sandlund; M M Hudson; W Kennedy; M Onciu; M B Kastan
Journal:  Pediatr Blood Cancer       Date:  2013-07-30       Impact factor: 3.167

7.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Authors:  C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.

Authors:  S Stilgenbauer; C Schaffner; A Litterst; P Liebisch; S Gilad; A Bar-Shira; M R James; P Lichter; H Döhner
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

Review 9.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

10.  Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Authors:  Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544
View more
  2 in total

1.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

2.  Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations.

Authors:  Jonathan Wong; Meaghan Wall; Gregory Philip Corboy; Nadine Taubenheim; Gareth Peter Gregory; Stephen Opat; Jake Shortt
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.